Key stakeholders gathered in the European Parliament yesterday to debate proposals on improving the clinical trials framework in Europe. At an event hosted by MEP Prof. Philippe Juvin and organised by EuropaBio, experts from patient groups, industry, academia, regulatory agencies, ethics committees and EU institutions gathered to further discuss ways to move forward in the upcoming revision of the Clinical Trials Directive and to present their respective proposals for the revision. Experts believe that a review of the current legislation will greatly benefit patients by improving the development of and access to innovative medicines while contributing to the goals of the EU 2020 strategy.
Central to the discussions were proposals to simplify current procedures as well as streamlining the trial approval process. EuropaBio believes that a harmonized content of the Clinical Trial application dossier, a scientific and ethical assessment and a single outcome is needed across all EU Member States to conduct innovative trials that benefit patients throughout the Union. Currently of the more than 650 biotechnological medicines undergoing clinical trials, many are produced by SMEs, which feel the administrative burden of the diverse implementation by Member States of the current rules even more acutely than larger pharmaceutical firms. Many of these clinical trials need to take place in numerous locations, therefore it is essential that extending clinical trials to multiple Member States does not trigger a costly and burdensome repetition of the scientific assessments by the different regulatory authorities.
Dr. Christiane Abouzeid, Head of Regulatory Affairs, BioIndustry Association (BIA) and topic leader for Clinical Trials at EuropaBio gave her expert opinion during the event. She emphasised the need for Europe to become a more attractive place for clinical research and development of new and innovative medicines. In order for this to be achieved, the current legislation on clinical trials needs to be modified to reduce administrative burdens across Member States, reducing costs for public and private sector researchers and ultimately speeding the time it takes for life-saving medication to reach patients. She stated: “Increased innovation in medicines needs the correct legislation in place so that procedures to bring medicines to the market are simplified. An open and informed debate on a new framework for clinical trials in Europe is necessary so that we can achieve better outcomes for patients, and further develop the knowledge-based economy in Europe”.
For more information:
Last updated on: 02/12/2011
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.